|
Volume 271, Number 25,
Issue of June 21, 1996
pp. 14971-14980
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
An Analysis of Retinoic Acid-induced Gene Expression and
Metabolism in AB1 Embryonic Stem Cells*
(Received for publication, January 30, 1996, and in revised form, March 28, 1996)
Anne C.
Chen
and
Lorraine J.
Gudas
From the Department of Pharmacology, Cornell University Medical
College, New York, New York 10021
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES
ABSTRACT
Murine embryonic stem cells such as the AB1 cell
line undergo differentiation in the presence of retinoic acid (RA) into
an extraembryonic epithelial cell type. This results in the activation
of genes such as Hoxa-1, Hoxb-1, laminin, collagen IV( 1), tissue
plasminogen activator, RAR , and CRABPII. The CRABPI gene is
regulated in an unusual fashion; CRABPI message and protein levels are
induced at low concentrations of RA, but induction is diminished at
higher concentrations. AB1 cells take up RA rapidly from the medium,
and the addition of low, exogenous concentrations of RA to the culture
medium results in very high intracellular RA concentrations. For
example, AB1 stem cells cultured in 5 nM
[3H]RA have an internal [3H]RA
concentration of 1-2 µM within the first hour. AB1 cells
also metabolize [3H]RA to more polar RA derivatives. The
half-life of RA in AB1 cells not previously exposed to RA is about
2-2.5 h versus 40-45 min in cells cultured for 2-3 days
in 1 µM exogenous RA. Thus, the enzyme(s) which
metabolize RA are induced or activated by RA. Furthermore, the local
concentration of RA required to elicit some biological responses may be
higher than previously thought.
INTRODUCTION
Retinoic acid (RA),1 a derivative of
vitamin A, plays a critical role in many cellular processes, including
cellular differentiation (1, 2) and embryogenesis (3, 4). RA can also
regulate the growth and differentiation of a large variety of
pre-malignant and neoplastic cell types, both in vivo and in
culture (2, 5, 6, 7, 8, 9). RA and several of its analogs have proven to be
efficacious as agents in the treatment of dermatologic disorders (10)
and as chemotherapeutic agents in the treatment of a number of human
cancers (11, 12, 13, 14, 15). However, the usefulness of retinoids such as RA in
the treatment of human disease is limited by their potent
teratogenicity (16, 17, 18) and rapid metabolism in many cell types (12,
19).
The mechanisms by which RA exerts its actions are not fully understood,
but several classes of proteins involved in mediating the cellular
response to RA have been identified. These cellular mediators include
at least two families of nuclear retinoid receptors (RARs and RXRs) and
two cellular retinoic acid-binding proteins (CRABPI and CRABPII). The
nuclear receptors are members of the steroid hormone receptor
superfamily and act as high affinity ligand-dependent
transcription factors (20, 21). In the presence of various RA isomers,
RARs and RXRs form heterodimers (21, 22, 23, 24, 25, 26, 27) that activate
differentiation-specific gene transcription by binding to retinoic acid
response elements in the promoter regions of RA-responsive target genes
(28, 29, 30, 31, 32, 33). The CRABPs are cytoplasmic, low molecular weight proteins
which are members of the fatty acid-binding protein superfamily (34).
The CRABPI and CRABPII proteins are highly related to one another and
bind to all-trans-RA with high, but varying affinities
(34, 35, 36, 37, 38). The functions of the CRABP proteins are not well understood,
but they are thought to play an important role in regulating the
metabolism of RA (39, 40, 41), and in regulating the intracellular levels
of RA in various tissues of the developing embryo. This hypothesis is
supported by the fact that CRABPI and CRABPII messages are expressed in
specific and distinct temporal and spatial patterns in many
tissues of the developing embryo, including those tissues that are
sensitive to the teratogenic effects of RA (42, 43, 44, 45, 46, 47, 48).
In response to RA, many teratocarcinoma cell lines (such as F9, P19,
and NT2) (49, 50, 51, 52) and embryonic stem cell lines (such as D3 and CCE)
(53, 54, 55) differentiate into cell types resembling those found in early
stages of the developing embryo. The AB1 murine embryonic stem cell
line (56) is a pluripotent stem cell line that has been used
extensively by many groups to investigate the effects of homozygous
deletions of a variety of developmentally-regulated (activin, inhibin,
follistatin, Hox b4) (57, 58, 59, 60, 61) and growth-related genes (p53,
c-myc) (59, 62) in tissue culture and in mice. Although AB1
cells have been widely used to study the effects of gene knockouts,
these cells have not been well characterized previously for their
response to RA. It is known, however, that AB1 cells undergo
differentiation after treatment with RA. In this paper, we characterize
the RA response of the AB1 embryonic stem cell line with regard to
RA-inducible gene expression and RA metabolism.
MATERIALS AND METHODS
Cell Culture and Reagents
AB1 murine embryonic stem cells
(56) were kindly provided by Dr. Allan Bradley (Baylor College of
Medicine, Houston, TX). AB1 cells were maintained in Dulbecco's
modified Eagle's medium supplemented with 10% heat-inactivated fetal
bovine serum, 2 mM glutamine, 1 × antibiotic/antimycotic
(consisting of 100 units/ml penicillin G sodium, 100 µg/ml
streptomycin sulfate, 0.25 µg/ml amphotericin B), 1 mM
sodium pyruvate, 100 µM minimal essential medium
non-essential amino acids, 1 µM -mercaptoethanol, and
103 units/ml leukemia inhibitory factor (LIF) at 37 °C
in 5% CO2. Embryonic stem cells are routinely cultured in
the presence of feeder cells to prevent spontaneous differentiation,
however, addition of LIF to the culture medium inhibits spontaneous
differentiation (63) and allows AB1 cells to be grown without feeder
cells. Addition of RA overcomes the inhibitory effects of LIF and
induces differentiation (64). All cell culture reagents were obtained
from Life Technologies, Inc. (Grand Island, NY). Retinoic acid
(Sigma) was dissolved in 100% ethanol and stored at
4 °C. Retinoic acid was added to cells 24 h after plating; the
final ethanol concentration did not exceed 1% of the total volume.
[3H]All-trans-retinoic acid and
[ -32P]dCTP were obtained from DuPont NEN (Boston,
MA).
Probes
An 800-base pair EcoRI fragment
containing the entire CRABPI cDNA was excised from the pMT-CRABPI
plasmid (40) for use as a probe for Northern blots. Similarly, an
876-base pair EcoRI/HindIII fragment containing
the entire CRABPII cDNA was excised from the pMT-CRABPII
plasmid.2 In addition, cDNA fragments
corresponding to the murine Hox b1, laminin B1, collagen IV ( 1), Tam
2.5 (tissue plasminogen activator), J6 serpin, Rex1, and actin genes
were excised from the following plasmids for use as probes. The pHox b1
(also known as Hox 2.9) plasmid was obtained from Dr. Joseph Grippo
(Hoffman LaRoche, Nutley, NJ) and contains a 435-base pair partial
cDNA specific for the murine Hox b1 gene within the
EcoRI/HindIII site of pGEM72f(+). The plamB1 5.5 plasmid contains a partial cDNA specific for the murine laminin B1
gene within the EcoRI site of pUC9 (65). The pcol 381 plasmid contains a partial cDNA specific for the murine collagen IV
( 1) gene within the EcoRI site of pUC9 (65). The Tam 2.5a
plasmid was kindly provided by Dr. Sidney Strickland (SUNY Stony Brook,
Stony Brook, NY) and contains the full-length murine tissue plasminogen
activator cDNA cloned into the EcoRI site of pKS+/
(66, 67). The pJ6-3 contains a partial cDNA specific for the murine
serpin gene within the PstI site of pUC9 (68). The
pRex1-2-5R plasmid contains a 1.7-kilobase pair fragment of the murine
Rex-1 gene cloned into the EcoRI site of pUC9 (69). The pUC
Act1 plasmid contains a partial cDNA specific for the murine actin gene within the PstI site of pUC9 (70).
RNA Isolation and Northern Blot Analysis
Total cellular RNA
was isolated by the guanidine isothiocyanate method of Chirgwin
et al. (71). Cells were plated in medium containing
103 units/ml LIF and treated with varying concentrations of
RA 24 h after plating. For the half-life experiment, AB1 cells
were cultured in the presence or absence of RA for 72 h, followed
by addition of 2 µg/ml actinomycin D-mannitol
(Sigma) for varying time periods. The mRNA was
size fractionated on 1.2% agarose, 2.2 M formaldehyde
gels, transferred to nitrocellulose, and hybridized to random
primer-labeled probe (72). Blots were washed once in 2 × SSC, 0.1%
SDS for 20 min at room temperature, once in 2 × SSC, 0.1% SDS at
60 °C, and once in 0.2 × SSC, 0.1% SDS at 60 °C.
Autoradiographs were quantitated by scanning densitometry using an LKB
densitometer (Pharmacia LKB, Piscataway, NJ). All of the Northern
experiments described in this paper were performed at least twice from
two independent RNA preparations.
Preparation of Cytoplasmic Protein Extracts and Polyacrylamide
Gel Electrophoresis
Cytoplasmic protein extracts were prepared as
described (40). Briefly, cells were resuspended in 10 mM
Tris, pH 7.4, and 7 mM -mercaptoethanol and solubilized
by Dounce homogenization. Supernatants were obtained by
ultracentrifugation at 100,000 × g for 1 h at 4 °C.
Protein concentration was determined by Bio-Rad protein assay (Bio-Rad)
as per the manufacturer's instructions. Bovine serum albumin
(Sigma) was used as a standard. 100 µg of protein
extract was incubated with 50 nM
[3H]all-trans-retinoic acid (DuPont NEN) and 2 mM dithiothreitol for 16 h at 4 °C in the presence
or absence of a 500-fold excess of unlabeled retinoic acid. The samples
were then analyzed by the nondenaturing polyacrylamide gel
electrophoresis (PAGE) technique described in Siegenthaler and Saurat
(73) and Siegenthaler et al. (74), except that samples were
resolved on a 12% polyacrylamide gel and 0.32 M Tris, pH
8.4, was used in the separating gel. The sample containing lanes of the
gel were sliced into 2-mm bands. Each gel slice was incubated overnight
at 50 °C in SOLVABLE tissue solubilizer (DuPont NEN) and tritiated
counts were quantitated by liquid scintillation counting in ATOMLIGHT
scintillant (DuPont NEN).
Extraction of Retinoids and HPLC Chromatography
Cells were
plated in 60-mm tissue cultures dishes at a density of 2 × 105 cells/dish in medium containing 103
units/ml LIF. 24 h after plating, varying concentrations of RA
were added to the cells for 72 h. On the day of labeling, medium
containing 5 or 50 nM
[3H]all-trans-RA (50 Ci/mmol) was added to
cells for various lengths of time as indicated. A separate control
consisting of radiolabeled RA in medium without cells was included
concurrently during the incubation period. Cells and one-quarter of the
labeled media were collected. Cells were scraped into
phosphate-buffered saline and retinoids were extracted immediately with
acetonitrile/butanol (50:50, v/v) and saturated potassium phosphate as
described previously by Boylan and Gudas (41). The organic phase
containing the labeled retinoids was separated from the aqueous phase
by centrifugation. The upper organic phase was collected and dried in a
SpeedVac (Savant). Samples were stored under argon for no longer than 1 week at 70 °C. High pressure liquid chromatography (HPLC) analysis
was performed using a Waters Millenium system (Millipore Corp.) to
separate the various retinoids. Samples were applied to an analytical
5-µm reversed-phase C18 column (Vydac, Hesperia, CA) at a
flow rate of 1.5 ml/min and the retinoids were separated using a
gradient from 0% acetonitrile (15 mM ammonium acetate, pH
6.5) to 100% acetonitrile (75). Non-labeled retinoid standards were
run concurrently and were monitored at a wavelength of 340 nm while a
Packard A-500 radiochromatography detector (Packard Instruments,
Downers Grove, IL) was employed to monitor the labeled retinoids.
RESULTS
AB1 Cells Express Retinoic Acid-inducible Genes
AB1 cells
were cultured in the presence of LIF, either without (AB1 stem cell
control), or with 1 µM RA for various lengths of time.
Upon treatment with RA, AB1 cells differentiate into cells resembling
extraembryonic endoderm. AB1 cells also behave similarly to other
embryonic stem cell lines and teratocarcinoma cell lines with respect
to the expression of many RA-responsive genes (Fig. 1).
Some early-response genes such as the homeobox-containing genes, Hox b1
(Fig. 1) (76, 77) and Hox a1 (data not shown) (78), are induced by RA,
while the zinc-finger containing Rex1 gene (55, 69) is down-regulated
by RA (Fig. 1). In addition, late-response genes such as collagen IV
( 1) (65), tissue plasminogen activator (Tam 2.5) (66, 67), laminin
B1 (65), and J6 serpin (68, 79) are induced after RA treatment (Fig.
1). The RAR gene is also induced in response to RA (data not shown).
All of these genes are expressed to similar degrees and with similar
kinetics as compared to what has been observed previously in F9
teratocarcinoma cells (6, 65, 67, 68, 69, 78, 80). These results
demonstrate that AB1 cells respond to RA by differentiating along an
epithelial pathway to parietal endoderm (2) and by inducing or
down-regulating a large number of genes.
Fig. 1.
Northern blot analysis of RA-inducible
genes. Total cellular RNA was prepared from AB1 cells grown in LIF
in the presence or absence of 1 µM RA for varying lengths
of time. 15 µg of RNA was loaded per lane and the resulting blots
were hybridized to random primer-labeled cDNA probes for Hox b1,
collagen IV ( 1), tissue plasminogen activator (Tam 2.5), laminin B1,
J6 serpin, Rex1, and actin (1 × 106 cpm/ml for all probes,
except 5 × 105 cpm/ml for actin).
Expression of CRABPI and CRABPII Genes
The genes encoding the
cellular retinoic acid-binding proteins, CRABPI and CRABPII, are also
regulated by RA (34). While CRABPII mRNA expression is induced
after RA treatment of both F9 and P19 cells (36), CRABPI message is
reduced by RA in F9 cells (35), but induced by RA in P19 cells (50).
The mechanism for the differential regulation of the CRABPI gene in F9
and P19 cells is not known. While less is known about the regulation of
the CRABPI gene (35, 81, 82), the transcriptional regulation of the
CRABPII gene has been reported to occur via high affinity RA response
elements (32, 33).
AB1 cells were cultured in LIF in the presence of a range of RA doses
for varying lengths of time. The CRABPI message is expressed in AB1
stem cells, but is induced to much higher levels upon treatment with RA
(Fig. 2). Induction of CRABPI gene expression is similar
to the induction of ``late'' response genes since CRABPI message
levels are still increasing 72 h after RA addition. Most
intriguing, though, is that the CRABPI message is induced at low
exogenous RA concentrations, but is almost extinguished by higher RA
concentrations. CRABPI mRNA is induced to the greatest extent after
AB1 cells have been exposed to 100 pM to 1 nM
RA (Fig. 2). In contrast, CRABPII mRNA is expressed at increasingly
higher levels as exogenous RA concentrations are raised, with maximal
expression detected upon addition of 1 µM RA (Fig.
2).
Fig. 2.
Expression of CRABPI and CRABPII genes in AB1
cells. Total cellular RNA was prepared from AB1 cells grown in LIF
in the presence or absence of the indicated concentrations of RA for
various lengths of time. Northern blots were hybridized to random
primer-labeled cDNA probes for CRABPI, CRABPII, and actin. Actin
message levels are not affected by RA treatment in AB1 cells.
Therefore, the Northern analyses are shown together with the CRABPI and
CRABPII gene expression quantitated and normalized to actin. This
experiment was performed twice; one representative experiment is
shown.
We have also examined the expression of other RA-responsive genes such
as Hox a1, Hox b1, collagen IV ( 1), laminin B1, and tissue
plasminogen activator. Thus far, all of the genes that have been
examined appear to behave like the CRABPII gene; the genes are most
highly induced at the highest RA concentrations (data not shown). These
data suggest that the CRABPI gene is regulated by RA in a different
manner from the CRABPII gene as well as from other RA-responsive genes.
Higher Levels of Functional CRABPI Protein Are Produced at Lower
Exogenous RA Concentrations
We next wanted to determine if the
increased level of CRABPI message expressed in cells treated with lower
doses of RA resulted in increased production of functional CRABPI
protein. AB1 cells were cultured in LIF and either 100 nM
or 1 µM RA for 72 h. Cytoplasmic protein extracts
were prepared from cells, incubated with [3H]RA, and
resolved by nondenaturing polyacrylamide gel electrophoresis (PAGE)
analysis (73, 74). The amount of functional CRABPI and CRABPII protein
expressed in a particular cell line can be visualized by virtue of its
ability to bind to [3H]RA. In addition, this procedure
allows us to separate and directly compare the amount of CRABPI and
CRABPII protein produced in a given cell line. The migration profiles
demonstrate that significant amounts of functional CRABPI and CRABPII
protein are produced in AB1 cells after treatment with 1 µM RA for 72 h (Fig. 3A).
CRABPI protein levels are about 1.4-fold higher than CRABPII protein
levels. After treatment with 100 nM RA (Fig.
3B), AB1 cells express an increased level of CRABPI protein
and a decreased level of CRABPII protein when compared to the levels of
CRABPI and CRABPII proteins expressed in cells treated with 1 µM RA (compare Fig. 3, A and B).
This results in a 5.0-fold higher level of CRABPI than CRABPII at 100 nM RA. These data indicate that as the concentration of
exogenously added RA is increased, CRABPII message and protein levels
also increase while CRABPI message and protein levels decrease.
Fig. 3.
PAGE analysis of [3H]RA binding
activity in AB1 cells. Cytoplasmic protein extracts were prepared
from AB1 cells cultured in LIF and 1 µM or 100 nM RA for 72 h. 100 µg of cytoplasmic protein
extract was incubated with 50 nM [3H]RA and
samples were resolved on 12% nondenaturing polyacrylamide gels.
Tritiated counts from 2-mm gel slices were quantitated by liquid
scintillation counting. The results are expressed as the total number
of 3H counts per min as a function of gel slice number,
with gel slice 40 corresponding to the bottom of the gel. The two peaks
corresponding to CRABPI and CRABPII protein are designated on the
graph. These peaks represent proteins that bind specifically to RA
since they can be eliminated when the protein extracts are incubated
with an excess of unlabeled RA (data not shown). Gel slices 33-39
correspond to the peak of unbound [3H]RA, although the
scales have been expanded so that the top of the peak of free
[3H]RA is not shown. [3H]RA protein binding
from AB1 cells grown in the presence of (A) 1 µM RA and (B) 100 nM RA are shown.
This experiment was performed twice with similar results.
Increased Induction of CRABPI Expression at Low RA Concentrations
Is Not a Result of Message Stabilization
To investigate whether
the increased RA responsiveness of the CRABPI gene at low RA
concentrations was a result of increased stability of CRABPI message,
we determined the half-life of the CRABPI message in cells treated with
high versus low exogenous RA concentrations. AB1 cells were
cultured in LIF and in the presence or absence of 1 µM or
1 nM RA for 72 h, then followed by treatment with
actinomycin D-mannitol for varying lengths of time. As
shown previously, CRABPI mRNA is induced after addition of either 1 nM or 1 µM RA, however, the highest message
levels are found at 1 nM RA (Fig. 4,
fourth vs. eighth lanes ). The half-life of the
CRABPI message is the same for AB1 cells grown in 1 µM or
1 nM RA (Fig. 4). In each case, the half-life of CRABPI
mRNA is approximately 9 h.
Fig. 4.
Half-life of CRABPI and CRABPII message in
AB1 cells. AB1 cells were grown in LIF in the presence or absence
of 1 µM or 1 nM RA for 72 h, then
treated with 2 µg/ml actinomycin D-mannitol for the
indicated lengths of time. Total cellular RNA was prepared and Northern
blots were hybridized to random primer-labeled cDNA probes for
CRABPI, CRABPII, and actin. The Northern analyses are shown together
with the quantitation of CRABPI and CRABPII gene expression normalized
to actin.
CRABPII message is induced to high levels only after treatment with 1 µM RA and the half-life of CRABPII message is longer than
9 h, since CRABPII message levels have not started to decline
9 h after treatment with actinomycin D-mannitol. These
results indicate that the increased level of CRABPI mRNA expressed
at low RA concentrations does not result from increased stabilization
of CRABPI message. Rather, these data suggest that CRABPI mRNA
induction by RA is regulated at the transcriptional level.
Kinetics of Retinoic Acid Metabolism in AB1 Cells
In the next
series of experiments, we characterized AB1 cells for their ability to
metabolize retinoic acid. Studies in our laboratory and by others have
shown that many cell types, including other teratocarcinoma cells and
embryonic stem cells, have the ability to metabolize RA to various
polar derivatives (41, 83, 84, 85).2 In F9 teratocarcinoma
cells, RA is metabolized relatively slowly in undifferentiated cells
(85); however, the rate of RA metabolism is dramatically increased when
F9 cells are cultured in the presence of 1 µM RA. Thus,
RA can induce its own metabolism in F9 cells. Work in our laboratory
has suggested that enzymes involved in the rapid metabolism of RA are
induced by 8 h after RA treatment of F9
cells.3
Most of the studies investigating RA metabolism in RA-differentiated
cells have been performed after culturing cells in the presence of high
exogenous RA concentrations (i.e. 1 µM RA)
(85). Fewer studies have been done to analyze RA metabolism in cells
cultured in the presence of varying concentrations of RA, and to
identify possible qualitative differences in the types of polar RA
metabolites generated.
AB1 cells were cultured in LIF in the absence or presence of 1 µM or 1 nM RA for 72 h, followed by
exposure to 5 or 50 nM [3H]RA for 1 or 2 h. After labeling, cells and media were harvested, retinoids were
extracted, and [3H]RA metabolites were resolved by HPLC.
Non-radiolabeled retinoid standards were added to each sample to permit
the identification of some of the radiolabeled retinoids. The HPLC
tracings of one such set of cell and media samples from a 2-h
incubation with 50 nM [3H]RA are shown in
Fig. 5A. After 2 h of incubation with
[3H]RA, both undifferentiated and RA-differentiated AB1
cells take up and metabolize significant amounts of
[3H]RA, as evidenced by the presence of a peak
corresponding to RA and by the presence of a large number of
[3H] polar RA derivatives inside the cell and in the
culture medium (Fig. 5A). The identities of all of these
polar [3H]RA metabolites are not known, although
unlabeled standards for 4-oxo-RA and 4-hydroxy-RA co-elute with some of
the peaks in the region of minute 10. A comparison of the types of
[3H]RA polar metabolites produced in AB1 cells cultured
in the presence of 1 µM or 1 nM RA does not
reveal any qualitatively different metabolites between the two culture
conditions. Rather, the differences among the three culture conditions
are more quantitative in nature.
Fig. 5.
Kinetics of RA metabolism in AB1 cells.
AB1 cells were cultured in LIF in the absence or presence of varying
concentrations of RA for 72 h. Cells were then labeled with either
5 or 50 nM [3H]RA for differing lengths of
time. Cells and one-quarter of the media were harvested, retinoids were
extracted, and reverse-phase HPLC analysis was performed to separate
the retinoids. Non-radiolabeled retinoids were included with each
sample as standards to determine the elution times of various
retinoids, including RA (data not shown). In Fig. 5A, the
HPLC tracings of cell and media samples, prepared from AB1 cells
cultured in the absence or presence of 1 µM or 1 nM RA for 72 h and then labeled for 2 h with 50 nM [3H]RA, are presented. The data for each
sample is plotted as tritiated counts per min versus time.
The peaks corresponding to [3H]all-trans-RA
and 3H-polar metabolites are indicated in the tracing.
Please note that the scales of the y axes are different for
the different samples. B, the kinetics of
[3H]RA metabolism in AB1 cells cultured as described
above, and then labeled with either 5 or 50 nM
[3H]RA for various times. The data are plotted as total
[3H]RA concentration versus time. To determine
total RA concentration, we first calculated the sum of
[3H]RA counts per min in the cells (C) and
media (M) for each time point. Since only one-quarter of the
media was assayed, the total [3H]RA counts were obtained
by taking the sum of C × 4 M for each time point. Since the
concentration of the starting [3H]RA was known, total
[3H]RA counts can be converted to [3H]RA
concentration (nM). C, the kinetics of
[3H]RA metabolism in various samples of AB1 cells grown
in a series of RA concentrations, and then labeled with 50 nM [3H]RA. The data are plotted as total
[3H]RA concentration versus time. This series
of experiments was performed three times with similar results; one
representative experiment is shown.
Analysis of multiple samples of both [3H]retinoids
extracted from cells and from the media at different times after the
addition of [3H]RA allowed the kinetics of
[3H]RA metabolism to be determined. The total RA
concentration for each time point was calculated by using the following
formula:
|
(Eq. 1)
|
where cpmC = tritiated RA counts in the cell sample,
cpmM = tritiated RA counts in the media sample, and
[3H]RAS = the number of tritiated cpm from
[3H]RA in the medium at the start of the experiment prior
to the addition of cells. Thus, the data in Fig. 5B are
plotted as the total amount of [3H]RA versus
time. The two panels depict the kinetics of [3H]RA
metabolism in AB1 cells incubated in the presence of either 50 (left panel) or 5 nM [3H]RA
(right panel). AB1 stem cells metabolize
[3H]RA relatively quickly, such that [3H]RA
has a t1/2 of about 2 h (Fig. 5B, open
circles). After 72 h of culture in the presence of 1 µM RA, the rate of [3H]RA metabolism in AB1
cells is dramatically increased, such that [3H]RA has a
t1/2 between 30 and 45 min (Fig. 5B, closed
triangles). The rate of [3H]RA metabolism in AB1
cells cultured in the presence of 1 nM RA resembles that
found in undifferentiated AB1 stem cells; the t1/2
of [3H]RA in both cases is approximately 2 h (Fig.
5B, closed squares). We also found that AB1 cells exhibited
similar kinetics of [3H]RA metabolism when they were
exposed to either 50 (left panel) or 5 nM
(right panel) [3H]RA (Fig. 5B). In
summary, in AB1 cells grown in the absence of RA or in the presence of
1 nM RA for 72 h, [3H]RA had a
t1/2 of 2-2.5 h. In AB1 cells grown in the presence
of 1 µM RA for 72 h, [3H]RA exhibited
a t1/2 of 40-45 min.
We next examined the kinetics of [3H]RA metabolism in AB1
cells cultured for 72 h in a greater range of exogenous RA
concentrations (Fig. 5C); this experiment is similar to that
shown in Fig. 5B, left panel, except that different cell
samples were initially cultured in each of four different RA
concentrations. In AB1 cells initially cultured in the absence of RA or
in the presence of 1, 10, or 100 nM RA for 72 h, the
t1/2 of [3H]RA was approximately
2 h; in cells cultured for 72 h in the presence of 1 µM RA, [3H]RA had a t1/2
of approximately 40 min (Fig. 5C). Thus, there is a striking
increase in the rate of [3H]RA metabolism when AB1 cells
are initially cultured in 1 µM RA as compared to lower
concentrations of RA (Fig. 5C).
In another series of experiments, a much higher concentration of
[3H]RA (500 nM) was added to AB1 cells which
had initially been cultured in the absence or presence of 1 µM RA for 48 h. Under these conditions the
t1/2 of [3H]RA was greater both for
cells grown in the absence or presence of 1 µM RA; the
t1/2 values are >6 and 1.5 h, respectively
(Table I). These results indicate that even when the
enzyme(s) which metabolize the [3H]RA are greatly induced
or activated by culturing cells in 1 µM RA, the enzymes
can be saturated by high substrate concentrations; this results in a
longer half-life for [3H]RA in the cells (Table I).
Table I.
Approximate half-life (t1/2) of [3H]RA when AB1 cells
are cultured under various conditions
| Initial culture condition prior to labeling with
[3H]RA |
Concentration of [3H]RA added
to the medium of AB1 cells in monolayer culture
|
| 5
nM |
50 nM |
500 nM
|
|
| Control, no added RA |
2.5
ha |
2.2 h |
>6.0 h |
| 1 nM
RA, 72 h |
NDb |
2.0 h |
ND |
| 10 nM RA, 72 h |
ND |
2.0 h |
ND |
| 100 nM RA, 48 h |
ND |
1.0 h |
ND |
| 100 nM RA, 72 h |
ND |
1.8 h |
ND |
| 1 µM RA, 48 h |
ND |
1.0 h |
1.5 h |
| 1 µM RA, 72 h |
40-45 min |
40-45 min |
ND |
|
|
a
These t1/2 values for
[3H]RA were obtained from multiple experiments;
t1/2 values varied less than 20% in the different
experiments and an average value is shown.
|
|
b
ND, not determined.
|
|
Intracellular RA Levels in AB1 Cells
The intracellular RA
concentration is a function of the rate of [3H]RA uptake
versus the rate of [3H]RA metabolism.
Regardless of the culture conditions, AB1 cells take up large amounts
of [3H]RA from the medium. When cells are labeled in
medium containing 5 or 50 nM [3H]RA, the
actual concentration of [3H]RA which is associated with
the cells is actually in the micromolar range (from 0.5 to 4.0 µM) within 2 h after the addition of
[3H]RA to the medium (Table II).
Table II.
Intracellular [3H]RA concentration in AB1 cells after
2 h of radiolabeling
AB1 cells were cultured as indicated, then exposed for 2 h to
various concentrations of [3H]RA. [3H]Retinoids
were isolated and separated by reverse-phase HPLC. Intracellular
[3H]RA concentrations were calculated by converting
cell-associated [3H]RA counts per minute to [3H]RA
concentration. The number of cpm of [3H]RA in the 2 ml of
starting medium is equal to 5 or 50 nM RA. The volume of
AB1 cells has been measured and 1 × 106 cells have a volume of
about 1 µl. Thus, the volume of one AB1 cell is about 1 pl. Cell
volumes have been reported from 0.5 pl for lymphoid cells to >10 pl
for a large fibroma cell (86, 87). Therefore, to calculate the
intracellular RA concentration, we used the following formula:
These data are from three different experiments; an average value
was calculated.
| Culture
condition prior to radiolabeling |
Concentration of
[3H]RA added to the medium of AB1 cells in monolayer culture
|
| 5 nM |
50 nM |
500 nM
|
|
| Control, no added
RA |
1.6 µM |
0.5 µM |
>50 µM
|
| 1 nM RA, 72 h |
3.7 µM |
2.3 µM |
NDa
|
| 1 µM RA, 48 h |
ND |
0.4 µM |
3.6 µM
|
| 1 µM RA, 72 h |
0.5 µM |
0.2 µM |
ND |
|
|
a
ND, not determined.
|
|
There are quantitative differences in the levels of
[3H]RA present in cells cultured under various conditions
(Fig. 5A, Table II). AB1 cells cultured for 72 h in the
absence of RA and then labeled with 5 nM
[3H]RA have an intracellular [3H]RA
concentration of about 1.6 µM (Table II, control), while
cells initially cultured in the presence of 1 µM
exogenous RA and then labeled have an intracellular
[3H]RA concentration of about 500 nM (Table
II, 1 µM RA). Cells grown in the presence of 1 nM RA for 72 h prior to labeling have an intracellular
concentration of approximately 3.7 µM
[3H]RA (Table II, 1 nM RA). These results
indicate that undifferentiated AB1 stem cells and AB1 cells initially
cultured in the presence of 1 nM RA contain significantly
higher levels of intracellular [3H]RA 2 h after
addition of the labeled RA than cells differentiated by initial culture
for 72 h with 1 µM RA (Table II).
This data suggests that the uptake of [3H]RA by the cells
occurs rapidly and that the metabolism of [3H]RA is
rate-limiting in untreated AB1 stem cells and in cells initially
cultured in the presence of 1 nM RA, presumably because the
enzyme(s) which metabolize [3H]RA are not very active
under these conditions. In contrast, AB1 cells initially cultured for
72 h in the presence of 1 µM exogenous RA exhibit a
higher level of enzymatic activity. Under these conditions, less
[3H]RA accumulates in the cells since a greater
proportion of the intracellular [3H]RA is metabolized
(Table II). However, even when the enzyme(s) which metabolize
[3H]RA are induced by 48 h of culture in 1 µM RA, a high concentration of [3H]RA, 500 nM, can saturate these metabolic enzymes and result in a
high level of [3H]RA within the cells (Table II).
Formation of Polar Metabolites in AB1 Cells
As previously
mentioned, AB1 cells metabolize [3H]RA into various polar
derivatives, which are then found in both the cells and in the media
(Fig. 5A). We measured the levels of 3H-polar
metabolites in cells (Fig. 6, top panel) and
in the media (Fig. 6, bottom panel) generated by AB1 cells
initially cultured in the presence or absence of 1 µM or
1 nM exogenous RA for 72 h, and then labeled for 1 or
2 h with 50 nM [3H]RA. The results are
plotted as the levels of 3H-polar metabolites (expressed as
counts per minute) versus each of the culture conditions.
When we examine the levels of 3H-polar metabolites present
in the cell, we find that AB1 cells initially cultured in the presence
of 1 µM RA for 72 h produce higher levels of
3H-polar metabolites in 1 h than AB1 stem cells or
cells previously cultured in 1 nM RA (Fig. 6, top
panel, open bars). The increased production of
3H-polar metabolites in cells cultured in 1 µM RA presumably results from the increased rate of
[3H]RA metabolism (Fig. 5, B and
C). After 2 h of labeling with [3H]RA,
the levels of 3H-polar metabolites in untreated stem cells
and in cells initially cultured in 1 nM RA continue to
increase, while 3H-polar metabolite levels in cells
initially cultured in 1 µM RA have already begun to
decline as these 3H-polar metabolites are further
metabolized to compounds which are not extracted in organic solvents
(Fig. 6, top panel, compare open bars to
hatched bars). By 6 h of exposure to [3H]RA,
the levels of 3H-polar metabolites in cells initially
cultured in 1 nM RA also decline (data not shown).
Fig. 6.
Formation of polar metabolites in AB1
cells. Cells were cultured as described in Table II, then labeled
for 1 or 2 h with 50 nM [3H]RA. Cells
and media were harvested, retinoids were extracted, and reverse-phase
HPLC analysis was performed. The amounts of 3H-polar
metabolites produced by cells grown under the different conditions were
quantitated by taking the sum (in counts per min) of all the
[3H]retinoids eluting in the polar region
(i.e. between minutes 6.8 and 12.3) of the HPLC tracing.
These data are plotted as tritiated counts per min of cell-associated
polar metabolites or 3H-polar metabolites in the medium
versus the culture condition over the prior 72 h. This
experiment was performed three times with similar results; one
representative experiment is shown. The data presented in this figure
were obtained from the same experiment as the data presented in Fig.
5B, left panel.
AB1 cells initially cultured for 72 h in the presence of 1 nM RA and labeled with [3H]RA for 1 h
produce a higher level of cell-associated
3H-polar metabolites (Fig. 6, top panel, open
bars, 10 9 M RA) but a lower
level of 3H-polar metabolites in the medium (Fig. 6,
bottom panel, open bars, 10 9 M RA)
than AB1 stem cells (Fig. 6, top and bottom panels,
open bars, stem). Since the kinetics of [3H]RA
metabolism by AB1 stem cells versus AB1 cells cultured
72 h in 1 nM RA are similar (Fig. 5B and
C), we conclude that the levels of 3H-polar
metabolites are higher within AB1 cells initially cultured
in 1 nM RA because a greater proportion of the polar
metabolites remains in these cells than in AB1 stem cells. Under these
same culture conditions (72 h of culture in the presence of 1 nM RA), the CRABPI mRNA level is very high (Fig. 2).
Therefore, one potential explanation for the high
intracellular levels of 3H-polar metabolites
under these conditions is that the polar metabolites are bound by
CRABPI protein in the cells. This explanation is consistent with data
from Fiorella and Napoli (88). There researchers previously
demonstrated that 4-hydroxy-RA and 4-oxo-RA, when bound to CRABPI, were
metabolized very slowly in testis microsomal extracts; in contrast,
unbound 4-hydroxy-RA and 4-oxo-RA had elimination
t1/2 values of 40 and 9 min, respectively.
DISCUSSION
RA-responsive Gene Expression
AB1 murine embryonic stem cells
differentiate into extraembryonic, parietal endoderm-like cells in
response to RA treatment (Fig. 1). As such, these cells behave
similarly to RA-responsive teratocarcinoma and other embryonic stem
cell lines characterized previously. All of the
differentiation-specific genes examined in this paper have been
characterized previously in other RA-responsive cell culture models as
being RA-responsive genes (2, 6, 65, 67, 68, 69, 78, 80). These include
both early response genes, such as homeobox genes (Hox a1 and Hox b1)
and zinc-finger containing transcription factors (Rex1), as well as
late response genes, such as CRABPII, RAR , laminin B1, collagen type
IV ( 1), and tissue plasminogen activator.
AB1 cells respond to exogenous RA in a dramatically different fashion
depending on whether they were previously cultured in the presence of
high or low exogenous concentrations of RA. This difference is marked
in particular by the expression of the CRABPI gene (Fig. 2). When
cultured for 72 h in the presence of high exogenous RA
concentrations (i.e. 1 µM RA), AB1 cells
express all of the differentiation-specific, RA-responsive target genes
discussed above, including the CRABPI and CRABPII genes. In contrast,
when cultured in the presence of low exogenous RA concentrations
(i.e. 1 nM RA), AB1 cells express the CRABPI
gene at a much higher level (Fig. 2). This effect is also seen at the
protein level. Higher amounts of functional CRABPI protein are observed
in cells treated with 100 nM RA when compared to those
treated with 1 µM RA (Fig. 3). This regulation of the
CRABPI gene presumably occurs at the transcriptional level and not
through message stabilization since the half-life of the CRABPI message
is similar in AB1 cells cultured in either high or low RA
concentrations (Fig. 4). That the CRABPI gene is transcriptionally
activated to a greater extent by low RA concentrations than by high
exogenous RA concentrations is of interest because concentrations of RA
in the range of 100 pM and 1 nM are more
physiologically relevant and more analogous to the concentrations of RA
reported in various tissues of the developing embryo (4). Additionally,
our data suggests that the CRABPI and CRABPII genes would be expressed
in an opposing fashion as the external RA concentration increased from
low to high concentration; the CRABPI mRNA level would decrease
while the CRABPII mRNA level would increase.
Our results regarding the higher levels of expression of the CRABPI
gene in AB1 cells cultured in the presence of low versus
high doses of exogenous RA (Fig. 2) can be interpreted in several ways.
One possibility is that the CRABPI promoter may contain both positive
and negative regulatory elements which are involved in the differential
response of the CRABPI gene in AB1 cells treated with low
versus high doses of RA. For example, a positively acting
transcription factor could be induced at both low and high doses of RA.
This factor would then bind to the CRABPI promoter and activate CRABPI
gene expression at low doses of RA. However, if a negatively acting
factor were induced in AB1 cells only at high exogenous RA
concentrations, this negative factor could then bind to a regulatory
element in the CRABPI promoter to repress CRABPI expression. Since the
regulatory elements of the CRABPI gene have not been well
characterized, this hypothesis cannot be tested at present.
Alternatively, the pluripotential AB1 cells may differentiate into
different cell types as a result of low versus high dose RA
treatment. A third potential explanation for the CRABPI gene expression
data presented here is that specific metabolites of RA such as 4-oxo-RA
influence the expression of the CRABPI gene; differences in the
production of these polar metabolites under different culture
conditions (Fig. 6) could result in different levels of CRABPI
mRNA. The relationships among RA metabolism, CRABPI gene
expression, and the ability of cells to differentiate deserve further
analysis in these AB1 embryonic stem cells and in other cell types in
the future.
Metabolism of Retinoic Acid
In addition to the differences in
gene expression described above, we also observed differences in RA
metabolism between AB1 cells cultured in the presence of high or low
concentrations of RA. After culture in the presence of high exogenous
RA concentrations, AB1 cells exhibited a dramatically increased rate of
[3H]RA metabolism to 3H-polar derivatives
(Fig. 5; Table I). In contrast, AB1 cells cultured in 1 nM
RA did not show an increase in the rate of [3H]RA
metabolism; they metabolized [3H]RA at about the same
rate as stem cells (Fig. 5; Table I). From the experiments reported
here it is clear that in AB1 cells, RA induces its own metabolism to
polar metabolites via a high capacity, low affinity enzyme system.
These polar metabolites are then further metabolized via an inducible
enzyme system. The uptake of RA appears to occur by a rapid, high
capacity mechanism such that under certain conditions, e.g.
in AB1 stem cells, the enzyme(s) which metabolize RA are rate-limiting
and large quantities of RA accumulate in the cells. Some information is
available concerning the enzymes which metabolize RA, and it is known
that a number of cytochrome P450 enzymes can metabolize RA (89, 90, 91, 92, 93, 94, 95, 96).
Reynolds et al. (97) have shown that metabolism of RA occurs
in human keratinocytes, but the enzyme(s) involved have not been
thoroughly studied. Various purified isozymes of microsomal cytochrome
P450 have been shown to be capable of metabolizing RA and other
retinoids (98). The identities of the enzyme(s) involved in RA
metabolism in these embryonic cells are unknown.
One of the most striking results of this study is that the actual
intracellular [3H]RA concentrations are extremely high
when AB1 cells are cultured in the presence of 1 nM to 1 µM exogenous RA in the medium (Table II). How much of
this cell-associated RA is associated with intracellular membranes
versus bound to proteins such as CRABPI, CRABPII, and the
RARs is not known. The Kd of CRABPI for RA has
previously been determined to be about 7 nM (38, 39, 99).
Thus, the intracellular RA concentration would be far above the
Kd of CRABPI even when these AB1 cells are cultured
in the presence of nanomolar concentrations of exogenous RA (Table II).
It would be expected that virtually all of the CRABPI protein in the
cell would be bound to RA, and that most of the RA in the cell would be
present as free RA or RA bound to membranes and/or other proteins.
We have made similar observations concerning the high intracellular RA
levels in other cell types cultured in the presence of exogenous
RA,4 so this result is not unique to AB1
cells. These results have important implications for studies in which
cells or tissues are cultured in the presence of high exogenous
concentrations of RA. The local concentrations of RA required to elicit
some biological responses may be higher than previously thought, based
on the exogenous concentrations of RA used to elicit biological
effects. Furthermore, such high intracellular concentrations of RA may
lead to the activation of extraneous receptors not normally activated
by endogenous retinoids. The fact that RA is so highly teratogenic may
also be explained in part by this ability of cells to accumulate RA
from the surrounding medium to extremely high intracellular levels.
FOOTNOTES
*
This work was supported in part by National Research Service
Fellowship Award F32 HD07560 from the National Institute of Child
Health and Human Development and by a Dermatology Foundation Research
Fellowship (to A. C. C.), and by National Institutes of Health Grant
R01 CA43796 (to L. J. G.). The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
``advertisement'' in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pharmacology,
Cornell University Medical College, 1300 York Ave., New York, NY 10021. Tel.: 212-746-6250; Fax: 212-746-8835 or 212-746-8858.
1
The abbreviations used are: RA,
all-trans-retinoic acid; 4-oxo-RA,
4-oxo-all-trans-retinoic acid; RAR,
all-trans-retinoic acid receptor; RXR,
9-cis-retinoic acid receptor, CRABP, cellular retinoic
acid-binding protein; LIF, leukemia inhibitory factor; PAGE,
polyacrylamide gel electrophoresis; HPLC, high pressure liquid
chromatography.
2
A. C. Chen, C. Stoner, and L. J. Gudas,
submitted for publication.
3
C. Achkar and L. J. Gudas, unpublished
observations.
4
A. C. Chen and L. J. Gudas, unpublished
data.
Acknowledgments
We thank Dr. John Wagner for critically
reading this manuscript, Dr. Jochen Buck for advice about the HPLC
system, and Taryn Resnick for editorial assistance.
REFERENCES
-
Sporn, M. B.,
Roberts, A. B.
(1983)
Cancer Res.
43,
3034-3040
[Free Full Text]
-
Gudas, L. J.,
Sporn, M. B.,
Roberts, A. B.
(1994)
The Retinoids: Biology, Chemistry, and Medicine
(Sporn, M. B.,
Roberts, A. B.,
Goodman, D. S.,
eds)
, p. 443, Raven Press
Ltd., New York
-
Eichele, G.
(1989)
Trends Genet.
5,
246-251
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hofmann, C.,
Eichele, G.
(1994)
The Retinoids: Biology, Chemistry, and Medicine
(Sporn, M. B.,
Roberts, A. B.,
Goodman, D. S.,
eds)
, p. 387, Raven Press
Ltd., New York
-
Fuchs, E.,
Green, H.
(1981)
Cell
25,
617-625
[CrossRef][Medline]
[Order article via Infotrieve]
-
Gudas, L. J.
(1991)
Semin. Dev. Biol.
2,
171-179
-
Jetten, A. M.,
Jetten, M. E.,
Shapiro, S. S.,
Poon, J. P.
(1979)
Exp. Cell Res.
119,
289-299
[CrossRef][Medline]
[Order article via Infotrieve]
-
Jetten, A. M.,
Kim, J. S.,
Sacks, P. G.,
Rearick, J. I.,
Lotan, D.,
Hong, W. K.,
Lotan, R.
(1990)
Int. J. Cancer
45,
195-202
[Medline]
[Order article via Infotrieve]
-
Lotan, R.,
Lotan, D.
(1981)
J. Cell. Physiol.
106,
179-189
[CrossRef][Medline]
[Order article via Infotrieve]
-
Peck, G. L.,
DiGiovanna, J. J.
(1994)
The Retinoids: Biology, Chemistry, and Medicine
(Sporn, M. B.,
Roberts, A. B.,
Goodman, D. S.,
eds)
, p. 631, Raven Press
Ltd., New York
-
Hill, D. L.,
Grubbs, C. J.
(1992)
Annu. Rev. Nutr.
12,
161-181
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hong, W. K.,
Itri, L. M.
(1994)
The Retinoids: Biology, Chemistry, and Medicine
(Sporn, M. B.,
Roberts, A. B.,
Goodman, D. S.,
eds)
, p. 597, Raven Press
Ltd., New York
-
Castaigne, S.,
Chomienne, C.,
Daniel, M. T.,
Ballerini, P.,
Berger, R.,
Fenaux, P.,
Degos, L.
(1990)
Blood
76,
1704-1709
[Abstract/Free Full Text]
-
Chomienne, C.,
Ballerini, P.,
Balitrand, N.,
Daniel, M. T.,
Fenaux, P.,
Castaigne, S.,
Degos, L.
(1990)
Blood
76,
1710-1717
[Abstract/Free Full Text]
-
Hong, W. K.,
Lippman, S. M.,
Itri, L. M.,
Karp, D. D.,
Lee, J. S.,
Byers, R. M.,
Schantz, S. P.,
Kramer, A. M.,
Lotan, R.,
Peters, L. J.,
Dimery, I. W.,
Brown, B. W.,
Goepfert, H.
(1990)
N. Engl. J. Med.
323,
795-801
[Abstract]
-
Lammer, E. J.,
Chen, D. T.,
Hoar, R. M.,
Agnish, N. D.,
Benke, P. J.,
Braun, J. T.,
Curry, C. J.,
Fernhoff, P. M.,
Grix, A. W.,
Lott, I. T.,
Richard, J. M.,
Sun, S. C.
(1985)
N. Engl. J. Med.
313,
837-841
[Abstract]
-
Sulik, K. K., Cook, C. S., and Webster, W. S. (1988) Development
103, (suppl.) 213-232
-
Armstrong, R. B.,
Ashenfelter, K. O.,
Eckhoff, C.,
Levin, A. A.,
Shapiro, S. S.
(1994)
The Retinoids: Biology, Chemistry, and Medicine
(Sporn, M. B.,
Roberts, A. B.,
Goodman, D. S.,
eds)
, p. 545, Raven Press
Ltd., New York
-
Warrell, R. P., Jr.,
de Thé, H.,
Wang, Z.-Y.,
Degos, L.
(1993)
N. Engl. J. Med.
329,
177-189
[Free Full Text]
-
Mangelsdorf, D. J.,
Thummel, C.,
Beato, M.,
Herrlich, P.,
Schütz, G.,
Umesono, K.,
Blumberg, B.,
Kastner, P.,
Mark, M.,
Chambon, P.,
Evans, R. M.
(1995)
Cell
83,
835-839
[CrossRef][Medline]
[Order article via Infotrieve]
-
Mangelsdorf, D. J.,
Umesono, K.,
Evans, R. M.
(1994)
The Retinoids: Biology, Chemistry, and Medicine
(Sporn, M. B.,
Roberts, A. B.,
Goodman, D. S.,
eds)
, p. 319, Raven Press
Ltd., New York
-
Bugge, T. H.,
Pohl, J.,
Lonnoy, O.,
Stunnenberg, H. G.
(1992)
EMBO J.
11,
1409-1418
[Medline]
[Order article via Infotrieve]
-
Heyman, R. A.,
Mangelsdorf, D. J.,
Dyck, J. A.,
Stein, R. B.,
Eichele, G.,
Evans, R. M.,
Thaller, C.
(1992)
Cell
68,
397-406
[CrossRef][Medline]
[Order article via Infotrieve]
-
Leid, M.,
Kastner, P.,
Lyons, R.,
Nakshatri, H.,
Saunders, M.,
Zacharewski, T.,
Chen, J.-Y.,
Staub, A.,
Garnier, J.-M.,
Mader, S.,
Chambon, P.
(1992)
Cell
68,
377-395
[CrossRef][Medline]
[Order article via Infotrieve]
-
Levin, A. A.,
Sturzenbecker, L. J.,
Kazmer, S.,
Bosakowski, T.,
Huselton, C.,
Allenby, G.,
Speck, J.,
Kratzeisen, C. L.,
Rosenberger, M.,
Lovey, A.,
Grippo, J. F.
(1992)
Nature
355,
359-361
[CrossRef][Medline]
[Order article via Infotrieve]
-
Yu, V. C.,
Delsert, C.,
Andersen, B.,
Holloway, J. M.,
Devary, O. V.,
Näär, A. M.,
Kim, S. Y.,
Boutin, J. M.,
Glass, C. K.,
Rosenfeld, M. G.
(1991)
Cell
67,
1251-1266
[CrossRef][Medline]
[Order article via Infotrieve]
-
Zhang, X.-K.,
Hoffmann, B.,
Tran, P. B.-V.,
Graupner, G.,
Pfahl, M.
(1992)
Nature
355,
441-444
[CrossRef][Medline]
[Order article via Infotrieve]
-
de Thé, H.,
Vivanco-Ruiz, M. D. M.,
Tiollais, P.,
Stunnenberg, H.,
Dejean, A.
(1990)
Nature
343,
177-180
[CrossRef][Medline]
[Order article via Infotrieve]
-
Langston, A. W.,
Gudas, L. J.
(1992)
Mech. Dev.
38,
217-228
[CrossRef][Medline]
[Order article via Infotrieve]
-
Smith, W. C.,
Nakshatri, H.,
Leroy, P.,
Rees, J.,
Chambon, P.
(1991)
EMBO J.
10,
2223-2230
[Medline]
[Order article via Infotrieve]
-
Vasios, G. W.,
Gold, J. D.,
Petkovich, M.,
Chambon, P.,
Gudas, L.
J.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
9099-9103
[Abstract/Free Full Text]
-
Aström, A.,
Pettersson, U.,
Chambon, P.,
Voorhees, J. J.
(1994)
J. Biol. Chem.
269,
22334-22339
[Abstract/Free Full Text]
-
Durand, B.,
Saunders, M.,
Leroy, P.,
Leid, M.,
Chambon, P.
(1992)
Cell
71,
73-85
[CrossRef][Medline]
[Order article via Infotrieve]
-
Ong, D. E.,
Newcomer, M. E.,
Chytil, F.
(1994)
The Retinoids: Biology, Chemistry, and Medicine
(Sporn, M. B.,
Roberts, A. B.,
Goodman, D. S.,
eds)
, p. 283, Raven Press
Ltd., New York
-
Stoner, C. M.,
Gudas, L. J.
(1989)
Cancer Res.
49,
1497-1504
[Abstract/Free Full Text]
-
Giguère, V.,
Lyn, S.,
Yip, P.,
Siu, C. H.,
Amin, S.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
6233-6237
[Abstract/Free Full Text]
-
MacGregor, T. M.,
Copeland, N. G.,
Jenkins, N. A.,
Giguère, V.
(1992)
J. Biol. Chem.
267,
7777-7783
[Abstract/Free Full Text]
-
Fiorella, P. D.,
Giguere, V.,
Napoli, J. L.
(1993)
J. Biol. Chem.
268,
21545-21552
[Abstract/Free Full Text]
-
Fiorella, P. D.,
Napoli, J. L.
(1991)
J. Biol. Chem.
266,
16572-16579
[Abstract/Free Full Text]
-
Boylan, J. F.,
Gudas, L. J.
(1991)
J. Cell Biol.
112,
965-979
[Abstract/Free Full Text]
-
Boylan, J. F.,
Gudas, L.
(1992)
J. Biol. Chem.
267,
21486-21491
[Abstract/Free Full Text]
-
Dencker, L.,
Annerwall, E.,
Busch, C.,
Eriksson, U.
(1990)
Development
110,
343-352
[Abstract/Free Full Text]
-
Dollé, P.,
Ruberte, E.,
Leroy, P.,
Morriss-Kay, G.,
Chambon, P.
(1990)
Development
110,
1133-1151
[Abstract/Free Full Text]
-
Perez-Castro, A. V.,
Toth-Rogler, L. E.,
Wei, L. N.,
Nguyen-Huu, M.
C.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
8813-8817
[Abstract/Free Full Text]
-
Ruberte, E.,
Dollé, P.,
Chambon, P.,
Morriss-Kay, G.
(1991)
Development
111,
45-60
[Abstract]
-
Ruberte, E.,
Friederich, V.,
Morriss-Kay, G.,
Chambon, P.
(1992)
Development
115,
973-987
[Abstract]
-
Ruberte, E.,
Friederich, V.,
Chambon, P.,
Morriss-Kay, G.
(1993)
Development
118,
267-282
[Abstract]
-
Vaessen, M. J.,
Meijers, J. H. C.,
Bootsma, D.,
Van Kessel, A. G.
(1990)
Development
110,
371-378
[Abstract/Free Full Text]
-
Strickland, S.,
Mahdavi, V.
(1978)
Cell
15,
393-403
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wei, L.-N.,
Blaner, W. S.,
Goodman, D. S.,
Nguyen-Huu, M. C.
(1989)
Mol. Endocrinol.
3,
454-463
[Abstract/Free Full Text]
-
Jones-Villeneuve, E. M.,
McBurney, M. W.,
Rogers, K. A.,
Kalnins, V. I.
(1982)
J. Cell Biol.
94,
253-262
[Abstract/Free Full Text]
-
Andrews, P. W.
(1984)
Dev. Biol.
103,
285-293
[CrossRef][Medline]
[Order article via Infotrieve]
-
Bradley, A.,
Evans, M.,
Kaufman, M. H.,
Robertson, E. J.
(1984)
Nature
309,
255-256
[CrossRef][Medline]
[Order article via Infotrieve]
-
Doetschman, T. C.,
Eistetter, H.,
Katz, M.,
Schmidt, W.,
Kemler, R.
(1985)
J. Embryol. Exp. Morphol.
87,
27-45
[Medline]
[Order article via Infotrieve]
-
Rogers, M. B.,
Hosler, B. A.,
Gudas, L. J.
(1991)
Development
113,
815-824
[Abstract]
-
McMahon, A. P.,
Bradley, A.
(1990)
Cell
62,
1073-1085
[CrossRef][Medline]
[Order article via Infotrieve]
-
Matzuk, M. M.,
Kumar, T. R.,
Bradley, A.
(1995)
Nature
374,
356-360
[CrossRef][Medline]
[Order article via Infotrieve]
-
Matzuk, M. M.,
Kumar, T. R.,
Vassalli, A.,
Bickenbach, J. R.,
Roop, D.
R.,
Jaenisch, R.,
Bradley, A.
(1995)
Nature
374,
354-356
[CrossRef][Medline]
[Order article via Infotrieve]
-
Shikone, T.,
Matzuk, M. M.,
Perlas, E.,
Finegold, M. J.,
Lewis, K. A.,
Vale, W.,
Bradley, A.,
Hsueh, A. J.
(1994)
Mol. Endocrinol.
8,
983-995
[Abstract/Free Full Text]
-
Matzuk, M. M.,
Lu, N.,
Vogel, H.,
Sellheyer, K.,
Roop, D. R.,
Bradley, A.
(1995)
Nature
374,
360-363
[CrossRef][Medline]
[Order article via Infotrieve]
-
Ramirez-Solis, R.,
Zheng, H.,
Whiting, J.,
Krumlauf, R.,
Bradley, A.
(1993)
Cell
73,
279-294
[CrossRef][Medline]
[Order article via Infotrieve]
-
Davis, A. C.,
Wims, M.,
Spotts, G. D.,
Hann, S. R.,
Bradley, A.
(1993)
Genes Dev.
7,
671-682
[Abstract/Free Full Text]
-
Williams, R. L.,
Hilton, D. J.,
Pease, S.,
Willson, T. A.,
Stewart, C.
L.,
Gearing, D. P.,
Wagner, E. F.,
Metcalf, D.,
Nicola, N. A.,
Gough, N. M.
(1988)
Nature
333,
684-687
-
Mummery, C. L.,
van den Eijnden-van Raaij, A. J. M.,
Feijen, A.,
Freund, E.,
Hulskotte, E.,
Schoorlemmer, J.,
Kruijer, W.
(1990)
Dev. Biol.
142,
406-413
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wang, S. Y.,
Gudas, L. J.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
5880-5884
[Abstract/Free Full Text]
-
Rickles, R. J.,
Strickland, S.
(1988)
FEBS Lett.
229,
100-106
[CrossRef][Medline]
[Order article via Infotrieve]
-
Rickles, R. J.,
Darrow, A. L.,
Strickland, S.
(1988)
J. Biol. Chem.
263,
1563-1569
[Abstract/Free Full Text]
-
Wang, S. Y.,
Gudas, L. J.
(1990)
J. Biol. Chem.
265,
15818-15822
[Abstract/Free Full Text]
-
Hosler, B. A.,
LaRosa, G. J.,
Grippo, J. F.,
Gudas, L. J.
(1989)
Mol. Cell. Biol.
9,
5623-5629
[Abstract/Free Full Text]
-
Spiegelman, B. M.,
Frank, M.,
Green, H.
(1983)
J. Biol. Chem.
258,
10083-10089
[Abstract/Free Full Text]
-
Chirgwin, J. M.,
Przybyla, A. E.,
MacDonald, R. J.,
Rutter, W. J.
(1979)
Biochemistry
18,
5294-5299
[CrossRef][Medline]
[Order article via Infotrieve]
-
Feinberg, A. P.,
Vogelstein, B.
(1984)
Anal. Biochem.
137,
266-267
[CrossRef][Medline]
[Order article via Infotrieve]
-
Siegenthaler, G.,
Saurat, J. H.
(1987)
Eur. J. Biochem.
166,
209-214
[Medline]
[Order article via Infotrieve]
-
Siegenthaler, G.,
Tomatis, I.,
Chatellard-Gruaz, D.,
Jaconi, S.,
Eriksson, U.,
Saurat, J. H.
(1992)
Biochem. J.
287,
383-389
-
McClean, S. W.,
Ruddel, M. E.,
Gross, E. G.,
DiGiovanna, J. J.,
Peck, G. L.
(1982)
Clin. Chem.
28,
693-696
[Abstract/Free Full Text]
-
Simeone, A.,
Acampora, D.,
Arcioni, L.,
Andrews, P. W.,
Boncinelli, E.,
Mavilio, F.
(1990)
Nature
346,
763-766
[CrossRef][Medline]
[Order article via Infotrieve]
-
Simeone, A.,
Acampora, D.,
Nigro, V.,
Faiella, A.,
D'Esposito, M.,
Stornaiuolo, A.,
Mavilio, F.,
Boncinelli, E.
(1991)
Mech. Dev.
33,
215-227
[CrossRef][Medline]
[Order article via Infotrieve]
-
LaRosa, G. J.,
Gudas, L. J.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
329-333
[Abstract/Free Full Text]
-
Wang, S. Y.
(1992)
J. Biol. Chem.
267,
15362-15366
[Abstract/Free Full Text]
-
Hu, L.,
Gudas, L. J.
(1990)
Mol. Cell. Biol.
10,
391-396
[Abstract/Free Full Text]
-
Wei, L.-N.,
Tsao, J.-L.,
Chu, Y.-S.,
Jeannotte, L.,
Nguyen-Huu, M.
C.
(1990)
DNA Cell Biol.
9,
471-478
[Medline]
[Order article via Infotrieve]
-
Kósa, K.,
Jones, C. S.,
De Luca, L. M.
(1995)
Cancer Res.
55,
4850-4854
[Abstract/Free Full Text]
-
Blaner, W. S.,
Olson, J. A.
(1994)
The Retinoids: Biology, Chemistry, and Medicine
(Sporn, M. B.,
Roberts, A. B.,
Goodman, D. S.,
eds)
, p. 229, Raven Press
Ltd., New York
-
Gubler, M. L.,
Sherman, M. I.
(1985)
J. Biol. Chem.
260,
9552-9558
[Abstract/Free Full Text]
-
Williams, J. B.,
Napoli, J. L.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
4658-4662
[Abstract/Free Full Text]
-
Bloom, W.,
Fawcett, D. W.
(eds)
(1975)
A Textbook of Histology
, 10th Ed.
, W. B. Saunders Co., Philadelphia
PA
-
Keith, C.,
Di Paola, M.,
Maxfield, F. R.,
Shelanski, M. L.
(1983)
J. Cell Biol.
97,
1918-1924
[Abstract/Free Full Text]
-
Fiorella, P. D.,
Napoli, J. L.
(1994)
J. Biol. Chem.
269,
10538-10544
[Abstract/Free Full Text]
-
Van Wauve, J.,
Coene, M. C.,
Cools, W.,
Goossens, J.,
Lauwers, W.,
Le
Jeune, L.,
Van Hove, C.,
Van Nyen, G.
(1994)
Biochem. Pharmacol.
47,
737-741
[CrossRef][Medline]
[Order article via Infotrieve]
-
Martini, R.,
Murray, M.
(1993)
Arch. Biochem. Biophys.
303,
57-66
[CrossRef][Medline]
[Order article via Infotrieve]
-
Vanden Bossche, H.,
Willemsens, G.,
Janssen, P. A. J.
(1988)
Skin Pharmacol.
1,
176-185
[Medline]
[Order article via Infotrieve]
-
Van Wauwe, J. P.,
Coene, M. C.,
Goossens, J.,
Van Nijen, G.,
Cools, W.,
Lauwers, W.
(1988)
J. Pharmacol. Exp. Ther.
245,
718-722
[Abstract/Free Full Text]
-
Barua, A. B.,
Gunning, D. B.,
Olson, J. A.
(1991)
Biochem. J.
277,
527-531
-
Van Wauwe, J. P.,
Coene, M. C.,
Goossens, J.,
Cools, W.,
Monbaliu, J.
(1990)
J. Pharmacol. Exp. Ther.
252,
365-369
[Abstract/Free Full Text]
-
Frolik, C. A.,
Roller, P. P.,
Roberts, A. B.,
Sporn, M. B.
(1980)
J. Biol. Chem.
255,
8057-8062
[Abstract/Free Full Text]
-
Bhat, P. V.,
Jetten, A. M.
(1987)
Biochim. Biophys. Acta
922,
18-27
[Medline]
[Order article via Infotrieve]
-
Reynolds, N. J.,
Fisher, G. J.,
Griffiths, C. E.,
Tavakkol, A.,
Talwar, H. S.,
Rowse, P. E.,
Hamilton, T.,
Voorhees, J. J.
(1993)
J. Pharmacol. Exp. Ther.
266,
1636-1642
[Abstract/Free Full Text]
-
Roberts, E. S.,
Vaz, A. D. N.,
Coon, M. J.
(1992)
Mol. Pharmacol.
41,
427-433
[Abstract]
-
Grippo, J. F.,
Gudas, L. J.
(1987)
J. Biol. Chem.
262,
4492-4500
[Abstract/Free Full Text]
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. D. Raman, N. P. Mongan, L. Liu, S. K. Tickoo, D. M. Nanus, D. S. Scherr, and L. J. Gudas
Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma
Carcinogenesis,
March 1, 2006;
27(3):
499 - 507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Martinez-Ceballos, P. Chambon, and L. J. Gudas
Differences in Gene Expression between Wild Type and Hoxa1 Knockout Embryonic Stem Cells after Retinoic Acid Treatment or Leukemia Inhibitory Factor (LIF) Removal
J. Biol. Chem.,
April 22, 2005;
280(16):
16484 - 16498.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Cerignoli, X. Guo, B. Cardinali, C. Rinaldi, J. Casaletto, L. Frati, I. Screpanti, L. J. Gudas, A. Gulino, C. J. Thiele, et al.
retSDR1, a Short-Chain Retinol Dehydrogenase/Reductase, Is Retinoic Acid-inducible and Frequently Deleted in Human Neuroblastoma Cell Lines
Cancer Res.,
February 1, 2002;
62(4):
1196 - 1204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Guo, A. Ruiz, R. R. Rando, D. Bok, and L. J. Gudas
Esterification of all-trans-retinol in normal human epithelial cell strains and carcinoma lines from oral cavity, skin and breast: reduced expression of lecithin:retinol acyltransferase in carcinoma lines
Carcinogenesis,
November 1, 2000;
21(11):
1925 - 1933.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Shen and L. J. Gudas
Molecular Cloning of a Novel Retinoic Acid-responsive Gene, HA1R-62, Which Is also Up-Regulated in Hoxa-1-overexpressing Cells
Cell Growth Differ.,
January 1, 2000;
11(1):
11 - 17.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. A. Lane, A. C. Chen, S. D. Roman, F. Derguini, and L. J. Gudas
Removal of LIF (leukemia inhibitory factor) results in increased vitamin A (retinol) metabolism to 4-oxoretinol in embryonic stem cells
PNAS,
November 9, 1999;
96(23):
13524 - 13529.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Chang and L.-N. Wei
Characterization of a Negative Response DNA Element in the Upstream Region of the Cellular Retinoic Acid-binding Protein-I Gene of the Mouse
J. Biol. Chem.,
April 11, 1997;
272(15):
10144 - 10150.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|